159 related articles for article (PubMed ID: 33709971)
1. Approach to patients with European Network for the Study of Adrenal Tumor stages I and II adrenocortical carcinomas.
Kastelan D; Muzurovic E; Dusek T
Curr Opin Endocrinol Diabetes Obes; 2021 Jun; 28(3):265-270. PubMed ID: 33709971
[TBL] [Abstract][Full Text] [Related]
2. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
3. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
4. Adrenocortical carcinoma.
Rodgers SE; Evans DB; Lee JE; Perrier ND
Surg Oncol Clin N Am; 2006 Jul; 15(3):535-53. PubMed ID: 16882496
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, treatment, and survival analysis of adrenocortical carcinomas: a multicentric study.
Souteiro P; Donato S; Costa C; Pereira CA; Simões-Pereira J; Oliveira J; Belo S; Santos AP; Cardoso H; Leite V; Carvalho D; Torres I
Hormones (Athens); 2020 Jun; 19(2):197-203. PubMed ID: 31823340
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Adrenocortical Carcinoma.
Vaidya A; Nehs M; Kilbridge K
Surg Pathol Clin; 2019 Dec; 12(4):997-1006. PubMed ID: 31672303
[TBL] [Abstract][Full Text] [Related]
7. Adrenocortical carcinoma.
Baudin E;
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):411-34. PubMed ID: 26038209
[TBL] [Abstract][Full Text] [Related]
8. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
Fassnacht M; Allolio B
Clin Endocrinol (Oxf); 2010 Nov; 73(5):561-5. PubMed ID: 20738315
[TBL] [Abstract][Full Text] [Related]
9. Clinical management of adrenocortical carcinoma.
Fassnacht M; Allolio B
Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):273-89. PubMed ID: 19500769
[TBL] [Abstract][Full Text] [Related]
10. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
[TBL] [Abstract][Full Text] [Related]
11. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
[TBL] [Abstract][Full Text] [Related]
12. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
13. Analysis of adjuvant chemotherapy in patients undergoing curative-intent resection of localized adrenocortical carcinoma.
Al Asadi A; Hubbs DM; Sweigert PJ; Baker MS; Kabaker AS
Am J Surg; 2021 Jul; 222(1):119-125. PubMed ID: 33168156
[TBL] [Abstract][Full Text] [Related]
14. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
15. Management of adrenocortical carcinoma.
Strosberg JR; Hammer GD; Doherty GM
J Natl Compr Canc Netw; 2009 Jul; 7(7):752-8; quiz 759. PubMed ID: 19635227
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.
Libé R; Borget I; Ronchi CL; Zaggia B; Kroiss M; Kerkhofs T; Bertherat J; Volante M; Quinkler M; Chabre O; Bala M; Tabarin A; Beuschlein F; Vezzosi D; Deutschbein T; Borson-Chazot F; Hermsen I; Stell A; Fottner C; Leboulleux S; Hahner S; Mannelli M; Berruti A; Haak H; Terzolo M; Fassnacht M; Baudin E;
Ann Oncol; 2015 Oct; 26(10):2119-25. PubMed ID: 26392430
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
[TBL] [Abstract][Full Text] [Related]
18. Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.
Puglisi S; Perotti P; Cosentini D; Roca E; Basile V; Berruti A; Terzolo M
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1125-1133. PubMed ID: 30117750
[TBL] [Abstract][Full Text] [Related]
19. Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome.
Williams AR; Hammer GD; Else T
Eur J Endocrinol; 2014 Jun; 170(6):829-35. PubMed ID: 24836548
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological Features Associated With the Prognosis of Patients With Adrenal Cortical Carcinoma: Usefulness of the Ki-67 Index.
Choi YM; Kwon H; Jeon MJ; Sung TY; Hong SJ; Kim TY; Kim WB; Shong YK; Lee JL; Song DE; Kim WG
Medicine (Baltimore); 2016 May; 95(21):e3736. PubMed ID: 27227935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
